These partnerships help fund the platform and expand patient options without shifting costs onto patients
Blood pressure reductions, triglyceride improvements, and glucose control all show further gains between week 24 and week 48
To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide
One of the most studied effects of Retatrutide is its potential impact on metabolic health
The reconstitution process is identical for both compounds standard aseptic technique, gentle swirling (never shaking), and refrigerated storage of reconstituted solutions
Its even a good choice for those who prefer non-GLP-1 medications, which can be combined for a tailored approach